Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

Improved safety window compared to single-target WEE1 inhibitors The Phase I clinical trial, set to launch in 2025, will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti ...

ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced ...

an oral WEE1 inhibitor aimed at treating various cancers. Dr. Oren Gilad, President and CEO of Aprea, highlighted the timing of Dr. Mirza’s formal inclusion in the team as pivotal.

“There’s pretty good preclinical evidence that there is synergistic activity when radiation therapy, and possibly also alkylating chemotherapy, is combined with a WEE1 inhibitor,” says Roth.

Dr. Pultar brings a wealth of oncology experience, notably in advancing WEE1 inhibitors, having previously guided azenosertib ...

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 ...

Presentations include preclinical data on Wee1/Myt1 inhibitor SGR-3515 and SOS1 inhibitor SGR-4174 Schrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515 ...

Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 30.24%, which has investors questioning if this is right time to ...

Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor ...

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer ...

Schrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor, will be presented at the American ...